Challenges and opportunies with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment

Expert Opinion on Investigational Drugs

Volumn 12, Issue 9, 2003, Pages 1511-1519

  Eldar Finkelman, Hagit ^a   Ilouz, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

GSK 3; Insulin resistance; Protein kinase inhibitors; Type 2 diabetes

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; ALSTERPAULLONE; AMINOPYRIDINE DERIVATIVE; BERYLLIUM; BETA CATENIN; CHIR 98014; CHIR 98023; CHIR 99021; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; GLYCOGEN SYNTHASE KINASE 3; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; LITHIUM DERIVATIVE; MALEIMIDE DERIVATIVE; METAL DERIVATIVE; NNC 57 0545; NNC 57 0588; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; PYRAZOLOPYRIMIDINE DERIVATIVE; QUINAZOLINE; SB 41528; SERINE PROTEINASE INHIBITOR; THIAZOLIDINE DERIVATIVE; THREONINE PROTEINASE; TOYOCAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 608; ZINC DERIVATIVE; ENZYME INHIBITOR;

COMPETITIVE INHIBITION; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; GLUCONEOGENESIS; GLUCOSE TRANSPORT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOLECULAR MIMICRY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG DESIGN;

DIABETES MELLITUS, TYPE 2; DRUG DESIGN; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INSULIN RESISTANCE;

EID: 0141740215     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.9.1511     Document Type: Review

References (83)

1. VIRKAMAKI A, UEKI K, KAHN CR: Protein-protein interaction in insulin signalling and the molecular mechanisms of insulin resistance. J. Clin. Invest. (1999) 103:931-943.
2. SALTIEL AR, PESSIN JE: Insulin signalling pathways in time and space. Trends Cell Biol. (2002) 12:65-71.
3. CROSS DA, ALESSI DR, VANDENHEEDE JR, MCDOWELL HE, HUNDAL HS, COHEN P: The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor-1 in the rat skeletal muscle cell line L6 is blocked by wortmannin but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf. Biocbem. J. (1994) 303:21-26.
4. WELSH GI, PROUD CG: Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem. J. (1993) 294:625-629.
5. MOULE SK, WELSH GI, EDGELL NJ, FOULSTONE EJ, PROUD CG, DENTON RM: Regulation of protein kinase B and glycogen synthase kinase-3 by insulin and beta-adrenergic agonist in rat epididymal fat cells. J. Biol. Chem. (1997) 272:7713-7719.
6. WOODGETT JR, COHEN P: Multisite phosphorylation of glycogen synthase. Molecular basis for the substrate specificity of glycogen synthase kinase-3 and casein kinase-II (glycogen synthase kinase-5). Biochim. Biophys. Acta (1984) 788:339-347.
7. WANG Y, ROACH PJ: Inactivation of rabbit muscle glycogen synthase by glycogen synthase kinase-3. Dominant role of the phosphorylation of Ser-640 (site-3a). J. Biol. Chem. (1993) 268:23876-23880.
8. SHULMAN GI: Cellular mechanisms of insulin resistance in humans. Am. J. Cardiol. (1999) 84:3J-10J.
9. ELDAR-FINKELMAN H, KREBS EG: Phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 impairs insulin action. Proc. Natl. Acad. Sci. USA (1997) 94:9660-9664.
10. TANTI JF, GR'EMEAUX T, VAN OBBERGHEN E, LE MARCHAND-BRUSTEL Y: Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signalling. J. Biol. Chem. (1994) 269:6051-6057.
11. HOTAMISLIGIL GS, PERALDI P, BUDAVARI A, ELLIS R, WHITE MF, SPIEGELMAN BM: IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α and obesity induced insulin resistance. Science (1996) 271:665-668.
12. NIKOULINA SE, CIARALDI TP, MUDAILAR S, MOHIDEEN P, CARTER L, HENRY RR: Potential role of GSK-3 in skeletal muscle insulin resistance Type 2 diabetes. Diabetes (2000) 49:263-271.
13. ELDAR-FINKELMAN H, SCHREYER SA, SHINOHARA MM, LEBOEUF RC, KREBS EG: Increased glycogen synthase kinase-3 activity in diabetes and obesity prone C57BL/6J mice. Diabetes (1999) 48:1662-1666.
14. HANSEN L, ARDEN K, RASMUSSEN S et al.: Chromosomal mapping and mutational analysis of the coding region of the glycogen synthase kinase-3alpha and beta isoforms in patients with NIDDM. Diabetologia (1997) 40(8):940-946.
15. WOODGETT JR: cDNA cloning and properties of glycogen synthase kinase-3. Methods Enzymol. (1991) 200:564-577.
16. WOODGETT JR: Judging a protein more than its name: GSK-3. Sci. STKE (2001) 100:RE12.
17. GRIMES CA, JOPE RS: The multifaceted roles of glycogen synthase kinase 3beta in cellular signalling. Prog. Neurobiol. (2001) 65:391-426.
18. ELDAR-FINKELMAN H: Glycogen synthase kinase-3: an emerging therapeutic target. Trends Mol. Med. (2002) 8:126-132.
19. CROSS DA, ALJESSI DR. COHEN P, ANDJELKOVICH M, HEMMINGS BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (1995) 378:785-789.
20. FIOL CJ, MAHRENHOLZ AM, WANG Y, ROESKE RW, ROACH PJ: Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J. Biol. Chem (1987) 262:14042-14048.
21. TER HAAR E, COLL JT, AUSTEN DA, HSIAO HM, SWENSON L, JAIN J: Structure of GSK3β reveals a primed phosphorylation mechanism. Nat. Struct. Biol. (2001) 8:593-596.
22. DAJANI R, FRASER E, ROE SM et al.: Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell (2001) 105:721-732.
23. WILLIAMS DD, MARIN O, PINNA LA, PROUD CG: Phosphorylated seryl and threonyl but not tyrosyl, residues are efficient specificity determinants for GSK-3β and Shaggy. FEBS Lett. (1999) 448:86-90.
24. PLOTKIN B, KAIDANOVICH O, TALIOR I, ELDAR-FINKELMAN H: Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J. Pharm. Exp. Ther. (2003) 305:974-980.
25. FRASER E, YOUNG N, DAJANI R et al.: Identification of the Axin and Frat binding region of glycogen synthase kinase-3. J. Biol. Chem. (2002) 277:2176-2185.
26. RUBINFELD B, ALBERT I, PORFIRI E, FIOL C, MUNEMITSU S, POLAKIS P: Binding of GSK-3 beta to the APC-beta-catenin complex and regulation of complex assembly. Science (1996) 272:1023-1026.
27. FARR GH 3rd, FERKEY DM, YOST C, PIERCE SB, WEAVER C, KIMELMAN D: Interaction among GSK-3, GBP, Axin and APC in Xenopus axis spccification. J. Cell. Biol. (2000) 148:691-702.
28. YOST C, TORRES M, MILLER J, HUANG E, KIMELMAN D, MOON R: The axis-inducing activity, stability and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. (1996) 10:1443-1454.
29. PEIFER M, PAI LM, CASEY M: Phosphorylation of the Drosophila. adherens junction protein Armadillo: roles for wingless signal and zeste-white 3 kinase. Dev. Biol. (1994) 166:543-556.
30. PEIFER M, POLAKIS P: Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science (2000) 287:1606-1609.
31. THOMAS GM, FRAME S, GOEDERT M, NATHKE I, POLAKIS P, COHEN P: A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of Axin and β-catenin. FEBS Lett. (1999) 458:247-251.
32. TAYLOR SS, KNIGHTON DR, ZHENG J, SOWADSKI JM, GIBBS CS, ZOLLER MJ: A template for the protein kinase family. Trends Biocbem. Sci. (1993) 18:84-89.
33. JOHNSON LN, NOBLE ME, OWEN DJ: Active and inactive protein kinases: structural basis for regulation. Cell (1996) 85:149-158.
34. TAYLOR SS, RADZIO-ANDZELM E: Protein kinase inhibition: natural and synthetic variations on a theme. Curr. Opin. Chem. Biol. (1997) 1:219-226.
35. DAVIES SP, REDDY H, CAIVANO M, COHEN P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. (2000) 351:95-105.
36. SCAPIN G: Structural biology in drug design: selective protein kinase inhibitors. Drug Discov. Today (2002) 7:601-611.
37. TOLEDO LM, LYDON NB, ELBAUM D: The structure-based design of ATP-site directed protein kinase inhibitors. Curr. Med. Chem. (1999) 6:775-805.
38. SOWADSKI JM, EPSTEIN LF, LANKIEWICZ L, KARLSSON R: Conformational diversity of catalytic cores of protein kinases. Pharmacol. Ther. (1999) 82:157-164.
39. TRAXLER P, FURET P: Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther. (1999) 82:195-206.
40. PARANG K, COLE PA: Designing bisubstrate analog inhibitors for protein kinases. Pharmacol. Ther. (2002) 93:145-157.
41. RING DB, JOHNSON KW, HENRIKSEN EJ et al.: Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes (2003) 52:588-595.
42. COGHLAN MP, CULBERT AA, CROSS DA et al.: Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. (2000) 7:793-803.
43. MANJI HM, MOORE GJ, CHEN G: Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol. Psychiatry (1999) 46:929-940.
44. JOPE RS: Antibipolar therapy: mechanism of action of lithium. Mol. Psych. (1999) 4:117-128.
45. KLEIN PS, MELTON DA: A Molecular Mechanism for the Effect of Lithium on Development. Proc. Natl. Acad. sci. USA (1996) 93:8455-8459.
46. RYVES WJ, HARWOOD AJ: Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem. Biophys. Res. Comm. (2001) 280:720-725.
47. CHENG K, CREACY S, LARNER J: 'Insulin-like' effects of lithium ion on isolated rat adipocytes. II. Specific activation of glycogen synthase. Mol. Cell. Biochem. (1983) 56:183-189.
48. NYFELER F, WALTER P: Effect of lithium on glycogen synthesis in bepatocytcs from rat liver. FEBS Lett. (1979) 108:197-199.
49. STAMBOLIC V, RUEL L, WOODGETT JR: Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr. Biol. (1996) 6:1664-1668.
50. CHENG K, CREACY S, LARNER J: 'Insulin-like' effects of lithium ion on isolated rat adipocytes. I. Stimulation of glycogenesis beyond glucose transport. Mol. Cell. Biochem. (1983) 56:177-182.
51. ORENA SJ, TORCHIA AJ, GAROFALO RS: Inhibition of GSK-3 stimulates glycogen synthase and glucose transport by distinct mechanisms in 3T3-L1 adipocytes. J. Biol. Chem. (2000) 275:15765-15772.
52. RYVES WJ, DAJANI R, PEARL L, HARWOOD AJ: Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem. Biophys. Res. Comm. (2002) 290:967-972.
53. ILOUZ R, KAIDANOVIDH O, GURWITZ D, ELDAR-FINKELMAN H: Inhibition of glycogen synthase kinase-3b by bivalent zinc ions: insight into the insulin-mimetic action of zinc. Biochem. Biophys. Res. Commun. (2002) 295:102-106.
54. COULSTON L, DANDONA P: Insulin-like effect of zinc on adipocytes. Diabetes (1980) 29:665-667.
55. MAY JM, CONTOREGGI CS: The mechanism of the insulin-like effects of ionic zinc. J. Biol. Chem. (1982) 257:4362-4368.
56. EZAKI O: IIb group metal ions (Zn2+, Cd2+, Hg2+) stimulate glucose transport activity by postinsulin receptor kinase mechanism in rat adipocyres. J. Biol. Chem. (1989) 264:16118-16222.
57. SIMON SF, TAYLOR CG: Dietary zinc supplementation attenuates hyperglycemia in db/db mice. Exp. Biol. Med. (2001) 226:43-51.
58. LECLERC S, GARNIER M, HOESSEL R et al.: Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. (2001) 276:251-260.
59. LEOST M, SCHULTZ C, LINK A et al.: Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem. (2000) 267:5983-5994.
60. PAP M, COOPER G: Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J. Biol. Chem. (1998) 273:19929-19932.
61. BIJUR GN, DE SARNO P, JOPE RS: Glycogen synthase kinase-3 beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J. Biol. Chem. (2000) 275:7583-7590.
62. RUBINFELD B, ROBBINS P, EL-GAMIL M, ALBERT I, PORFIRI E, POLAKIS P: Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science (1997) 25:1790-1792.
63. LOCHHEAD PA, COGHLAN M, RICE SQ, SUTHERLAND C: Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression. Diabetes (2001) 50:937-946.
64. WITHERINGTON J, BORDAS V, HAIGH D et al.: 5-Aryl-pyrazolo[3,4-b]pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. (2003) 13:1581-1584.
65. NIKOULINA SE, CIARALDI TP, MUDALIAR S, CARTER L, JOHNSON K, HENRY RR: Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes (2002) 51:2190-2198.
66. HENRIKSEN EJ, KINNICK TR, TEACHEY MK et al.: Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats. Am. J. Physiol. Endocrinol. Metab. (2003) 284:E892-E900.
67. CLINE GW, JOHNSON K, REGITTNIG W et al.: Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. Diabetes (2002) 51:2903-2910.
68. VX-608. IDdb3 Drug Report (2003).
69. KINETEK: GSK-3β inhibitors. IDdb3 Drug Report (2002).
70. NAERUM L, NORSKOV-LAURITSEN L, OLESEN PH: Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors. Bioorg. Med. Chem. Lett. (2002) 12:1525-1528.
71. NOVO NORDISK: GSK-3 inhibitors. IDdb3 Drug Report (2002).
72. MARTINEZ A, ALONSO M, CASTRO A, PEREZ C, MORENO FJ: First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. (2002) 45:1292-1299.
73. LINDSAY MA: Peptide-mediated cell delivery: application in protein target validation. Curr. Opin. Pahrmacol. (2002) 2:587-594.
74. HAWIGER J: Noninvasive intracellular delivery of functional peptides and proteins. Curr. Opin. Chem. Biol. (1999) 3:89-94.
75. HEINEMANN L, PFUTZNER A, HEISE T: Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary delivery. Curr. Pharm. Des. (2001) 14:1327-1351.
76. SENEL S, KREMER M, NAGY K, SQUIER C: Delivery of bioacrive peptides and proteins across oral (buccal) mucosa. Curr. Pharm. Biotechnol. (2001) 2:175-186.
77. DENNIS MS, ZHANG M, MENG YG et al.: Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. (2002) 277:35035-35043.
78. MARKUSSEN J, HAVELUND S, KURTZHALS P et al.: Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia (1996) 39:281-288.
79. WAKEFIELD JG, STEPHENS DJ, TAVARE JM: A role for glycogen synthase kinase-3 in mitotic spindle dynamics and chromosome alignment. J. Cell Sci. (2003) 116:637-646.
80. HOEFLICH KP, LUO J, RUBIE EA, TSAO MS, JIN O, WOODGETT JR: Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature (2000) 406:86-90.
81. (+)-binding properties of a recombinant protein-tyrosine kinase derived from the human insulin receptor. Proc. Natl. Acad. Sci. USA (1990) 87:2805-2809.
82. WANG QM, PARK IK, FIOL CJ, ROACH PJ, DEPAOLI-ROACH AA: Isoform differences in substrate recognition by glycogen synthase kinases 3 alpha and beta in the phosphorylation of phosphatase inhibitor 2. Biochemistry (1994) 33:143-147.
83. VERTEX: IDdb3 report (2003).